Regeneron Pharmaceuticals
Coverage of Regeneron Pharmaceuticals in the Nexus archive.
- STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field
The FDA's shifts are a top concern for the gene therapy field, even at a meeting in Rome. Recent approvals of rare disease treatments have been highlighted as reasons for optimism. The departure of Vinay Prasad, the FDA's vaccine chief, is also seen as potentially promising.
- Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
President Donald Trump announced a deal with Regeneron Pharmaceuticals to lower drug prices under the most-favored-nation initiative, including discounted Medicaid pricing and a $225 price for cholesterol drug Praluent on the TrumpRx website. The agreement, part of broader efforts to reduce healthcare costs ahead of midterms, also includes $27 billion in U.S. R&D investments and expedited FDA approval for Regeneron's gene therapy.
- The FDA gives the green light to the first gene therapy for deafness
The FDA has approved the first gene therapy for deafness, developed by Regeneron Pharmaceuticals, marking a significant medical milestone for treating a rare form of the condition.
- Watch live: Trump gives remarks on health care affordability
President Trump is hosting a White House event to address health care affordability and is expected to announce a new agreement with pharmaceutical company Regeneron under his 'Most Favored Nation' initiative. This marks the 17th such agreement by the administration.